Zantac is Blamed For Causing Gastric Cancer

Yet another type of cancer has been added to the list of Zantac's alleged side effects

Thursday, April 23, 2020 - A woman from Illinois claims that the popular heartburn medication she took for around 20 years is responsible for her Gastric cancer. According to Legal Examiner, the complaint states that the woman started using Zantac in 2000 and continued until her cancer diagnosis in 2018 and that the plaintiff carefully followed the manufacturer's usage instructions. Zantac attorneys representing American families nationwide, offer a free consultation and no obligation to file a claim.

Gastric cancer, like others, may not be detected for years after it develops and Gastric cancer symptoms can mask themselves as stomach discomfort and bloating, ironically the same symptoms that cause an individual to reach for a Zantac in the first place. The Examiner explains further, telling readers, "Gastric cancer spreads through to the outer layers of the stomach, and in the early stages, it can cause symptoms like indigestion and stomach discomfort, a bloated feeling after eating, mild nausea, loss of appetite, and heartburn. In the more advanced stages, it can cause blood in the stool, vomiting, weight loss for no known reason, stomach pain, and a buildup of fluid in the abdomen."

Thousands of individuals are filling suit against Sanofi, the maker of Zantac for causing any of a variety of cancer from stomach and bladder to prostate cancer. Individuals that took the heartburn and acid reflux medication before their cancer diagnosis, and also the loved ones of those who have done so and died may be entitled to file a claim against the company for failing to warn consumers of the dangers of taking the drug. Zantac and several other heartburn medications contain a naturally-occurring, yet carcinogenic chemical called N-Nitrosodimethylamine (NDMA) in levels that were previously thought to be harmless. The mediation became a billion-dollar seller for the company after because of its effectiveness in reducing the amount of acid the stomach produces. Zantac was also prescribed to treat and prevent stomach ulcers. It was not until October of 2018 that Valisure, an online pharmacy whose marketing angle is to test drugs for potency discovered levels of the carcinogen that were orders of magnitude greater than previously thought. The company reported these findings to the US Food and Drug Administration who then recalled and banned the medication. NDMA was first used as an additive to rocket fuel and later used by cancer researchers to induce tumors in lab rats and was thought by the FDA to be merely an impurity.

To the company's credit, Sanofi voluntarily recalled Zantac from over the counter sales in 2019 to test the product more thoroughly. According to the FDA, "As a precautionary measure, Sanofi on Friday, October 18, initiated a voluntary recall of all Zantac OTC (over-the-counter) in the United States. This includes Zantac 150, Zantac 150 Cool Mint, and Zantac 75. Zantac tablets are an oral, over-the-counter product to prevent and relieve heartburn associated with acid ingestion and sour stomach. On September 13, 2019, the U.S Food and Drug Administration issued a public statement alerting that some ranitidine medicines, including Zantac OTC, could contain NDMA at low levels and asked manufacturers to conduct testing."

The FDA's Zantac recall comes as too little too late for thousands of people with stomach, bladder, esophageal, intestinal, prostate, and other cancer and for the loved ones of those who have died. Valisure questioned the stability of the molecule in high heat as well as when it interacts with nitrates, preservatives in processed meat, within the stomach.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.